Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?
Elettra MerolaTeresa Alonso GordoaPanpan ZhangTaymeyah Al-ToubahEleonora PellèAgnieszka Kolasińska-ĆwikłaWouter ZandeeFaidon LaskaratosLouis de MestierAngela LamarcaJorge HernandoJaroslaw CwiklaJonathan StrosbergWouter de HerderMartin CaplinMauro CivesRachel van LeeuwaardePublished in: The oncologist (2020)
The results of the study call into question the antiproliferative activity of somatostatin analogs (SSAs) in pancreatic neuroendocrine tumors with Ki-67 ≥10%. Patients with grade 2 tumors and with hepatic tumor load ≤25% appear to derive higher benefit from SSAs. Prospective studies are needed to validate these results to optimize tailored therapeutic strategies for this specific patient population.